Is there a domestic version of Binimetinib and its market supply status?

Binimetinib is an oral small molecule inhibitor targeting MEK1/2. It is often used in combination with BRAF inhibitors (such as trastuzumab) to treat advanced melanoma and other specific solid tumors carrying BRAF V600 mutations. Although the drug has been approved for marketing in Europe, the United States and Hong Kong, as of now, bimetinib has not been approved for marketing in mainland China, and there is no domestic version available. Therefore, if patients need to use the drug, they must rely on overseas channels to purchase it.

Due to the lack of localization, there are currently no bimetinib products developed or copied by local pharmaceutical companies on the Chinese mainland market. Current clinical use relies entirely on original drugs or overseas generic drugs, mainly from drug channels in Hong Kong, India, Laos and other places. Among them, the Hong Kong version of the original version of Novartis is 15 mg × 84 tablets. Each box sells for about more than 10,000 yuan. It is a high-priced drug and is suitable for patients who have high requirements for the original production quality of the drug if their economic conditions permit.

In contrast, the generic version of bimetinib produced by the Lao Lucius (Luzhou) pharmaceutical company has attracted attention because of its lower cost and more affordable price. The current price of this generic drug is about 6,000 yuan per box, which is almost half the price of the original drug. It has become an alternative choice for many self-paying patients or those without medical insurance coverage. Although the efficacy and bioequivalence of generic drugs may not be completely consistent with that of original drugs, most patients report that their therapeutic effects are still guaranteed.

In summary, there is no domestic version of bimetinib in my country, and the market supply completely relies on overseas channels. Currently, there are two common versions available on the market: the Hong Kong version of the original drug and the Lao generic version. When choosing medication, patients need to weigh the efficacy, affordability, and safety of the access channels. It is recommended to purchase medication through formal overseas medical service platforms or under the guidance of a doctor to ensure medication safety and therapeutic effect. With the increase in clinical demand, bimetinib is expected to gradually promote its launch and localized production in China in the future.

Reference materials:https://www.drugs.com/